In Vancouver, Canada, BioHarvest Sciences Inc CEO Ilan Sobel recently announced two key business development and science appointments to lead initiatives within the newly launched CDMO Services business unit. Professor Itai Mairose has been appointed Senior Scientist in Artificial Intelligence to lead development initiatives in the unit, using his expertise in plant computational genomics.

Professor Mairose is a globally recognized expert in plant computational genomics, known for his multidisciplinary approach combining computing with biological research. His work pioneering the use of artificial intelligence in genome editing and evolutionary studies has led to groundbreaking discoveries published in prestigious scientific journals.

Matt Zrebiec was introduced as Vice President of Business Development, bringing 23 years of experience in the pharmaceutical sector to drive new business for the CDMO business unit. Zrebiec’s experience in branded specialty, biotech, generic and CDMO pharmaceuticals positions him well to contribute to BioHarvest’s growth and success in business development.

These appointments underscore BioHarvest’s commitment to driving innovation and excellence within its CDMO Services business unit. Using the expertise of experienced professionals such as Zrebiec and Professor Mairose, the company aims to advance its strategic goals and deliver value to stakeholders.

For more information, contact Proactive North America at +1 604-688-8158 or email

By Samantha Johnson

As a dedicated content writer at, I immerse myself in the art of storytelling through words. With a keen eye for detail and a passion for crafting engaging narratives, I strive to captivate our audience with each piece I create. Whether I'm covering breaking news, delving into feature articles, or exploring thought-provoking editorials, my goal remains constant: to inform, entertain, and inspire through the power of writing. Join me on this journalistic journey as we navigate through the ever-evolving media landscape together.

Leave a Reply